| T.R | Title | User | Personal
Name | Date | Lines |
|---|
| 380.1 | Interferon | LEDS::DJBROWN | | Thu Feb 11 1993 15:09 | 11 |
| They make alpha interferon and gamma interferon. Their products
are licensed and sold through a larger company, whose name escapes me.
If you're serious about buying the stock, you really might want to
read up on the company. Also, check for recent stories. About a
month ago, they announced that they didn't expect to continue their
rate of earnings growth, and their stock dropped 25% (so far).
If you believe in market timing, watch them carefully. They've
gone from 20 to 45 and back three times in the last three years.
I caught the first two cycles, but missed the last (bought DEC instead).
|
| 380.2 | BIOGEN | AUDIO::MCGREAL | | Fri Feb 12 1993 17:25 | 20 |
|
Thanks for the advice. I never buy a stock that I don't atleast
read the perspectus on. WSJ is my morning paper. Money mag.
isn't bad either. My local library has a nice computerized search
facility which could also be useful for digging up old info on them.
From what I can understand about interferon, it is a protein that
is created in response to infection and is used to curb further
spreading of the infection within a cell.
Some analysts are still saying that BGEN is a good buy at $35.
You seem to have had good fortune with timing the stock.
Thanks for the information.
Pat
|
| 380.3 | Very Cyclical | BOSBEN::LASHER | VMS Partner -- Boston Sales Support | Wed May 12 1993 03:44 | 14 |
| They have several new or "in development" drugs that will be used to
treat Hepatitis B and C, AIDS, various cancers, and to prevent blood
clotting during heart/artery/vein surgical procedures.
They seem to have a solid future, although, as stated earlier, they are
very volatile. I've been for one ride already. Bought at 25, went to
about 47, (didn't sell), went back to around 27, now back to around 36.
Most of their revenue (at least 85%) is dependent on other companies
(like Merck and Plough-Scherer sp?) reselling their product, so they
are not in direct control of their own revenues.
They finished strong in 1992 largely due to the fact that in a law was
passed requiring one of their vaccines for any employees covered by OSHA.
|
| 380.4 | ENZON/Biotech suggestion ? | CNTROL::AGUPTA | | Tue Jun 14 1994 02:01 | 24 |
|
Hi,
Based upon recommendation by a broker I bought ENZON stock at $6.00 about a
year ago. Now the stock is trading at 2 7/8 bid 3 1/8 asked. (For past two
weeks the price have been exactly this; it didn't move at all. The volume is
low 3,000 to 20,000 stocks per day. Could it be considered building a base ? )
Also this company recently issued stocks for $15 million investment from
another investor. This provided them cash but diluted the existing stocks.
I was wondering what is your opinion on this. Should I hold on or
cut my losses. When I talk to the broker he recommends to buy some more
because he believes it is a good value.
I know that the biotech stocks are down due to changes in health plans but
then again these stocks may have been oversold.
Thanks
Abhijit
PS. Rather than starting a new note, I am taking the liberty to attach this
note here.
|
| 380.5 | exit | POBOX::PATEL | | Wed Jun 15 1994 17:07 | 6 |
| The question is "Do you need the Money" .OR. "Did you buy this with a
1 year Horizon?".
Secondly, take a look at the company's product pipeline and the amount
of cash they have and the rate at which they are consuming the cash.
Ken
|